DK1633440T3 - Farmaceutisk sammensætning omfattende proteiner og/eller polypeptider og kolloidale partikler - Google Patents
Farmaceutisk sammensætning omfattende proteiner og/eller polypeptider og kolloidale partiklerInfo
- Publication number
- DK1633440T3 DK1633440T3 DK04727664T DK04727664T DK1633440T3 DK 1633440 T3 DK1633440 T3 DK 1633440T3 DK 04727664 T DK04727664 T DK 04727664T DK 04727664 T DK04727664 T DK 04727664T DK 1633440 T3 DK1633440 T3 DK 1633440T3
- Authority
- DK
- Denmark
- Prior art keywords
- proteins
- colloidal particles
- polypeptides
- polypeptide
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46270103P | 2003-04-15 | 2003-04-15 | |
PCT/IL2004/000327 WO2004091723A1 (en) | 2003-04-15 | 2004-04-15 | Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1633440T3 true DK1633440T3 (da) | 2008-09-08 |
Family
ID=33299976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04727664T DK1633440T3 (da) | 2003-04-15 | 2004-04-15 | Farmaceutisk sammensætning omfattende proteiner og/eller polypeptider og kolloidale partikler |
Country Status (15)
Country | Link |
---|---|
US (1) | US20070167359A1 (de) |
EP (1) | EP1633440B1 (de) |
JP (1) | JP2006523683A (de) |
CN (1) | CN1774281B (de) |
AT (1) | ATE395101T1 (de) |
AU (1) | AU2004229253B2 (de) |
BR (1) | BRPI0409424B8 (de) |
CA (1) | CA2522179C (de) |
DE (1) | DE602004013769D1 (de) |
DK (1) | DK1633440T3 (de) |
ES (1) | ES2307009T3 (de) |
MX (1) | MXPA05010926A (de) |
PL (1) | PL1633440T3 (de) |
PT (1) | PT1633440E (de) |
WO (1) | WO2004091723A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2554161A1 (de) | 2011-08-02 | 2013-02-06 | LFB Biotechnologies | Pharmazeutische Zusammensetzung enthaltend Faktor VII in Mizellen verkapselt |
GB201417589D0 (en) * | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4348384A (en) * | 1980-10-17 | 1982-09-07 | Dainippon Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral administration containing coagulation factor VIII or IX |
DE68925966T2 (de) * | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5527528A (en) * | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
US5225212A (en) * | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
JPH0482839A (ja) * | 1990-07-20 | 1992-03-16 | Green Cross Corp:The | 蛋白質類・脂質小体複合体 |
NZ260909A (en) * | 1993-07-05 | 1995-04-27 | Takeda Chemical Industries Ltd | Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution |
US5874075A (en) * | 1993-10-06 | 1999-02-23 | Amgen Inc. | Stable protein: phospholipid compositions and methods |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
AU1916295A (en) * | 1994-02-08 | 1995-08-29 | Amgen, Inc. | Oral delivery of chemically modified proteins |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
JP2001508783A (ja) * | 1997-01-29 | 2001-07-03 | ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー | Peg化法 |
WO1999055306A1 (en) * | 1998-04-27 | 1999-11-04 | Opperbas Holding B.V. | Pharmaceutical composition comprising factor viii and neutral liposomes |
DE60026030T2 (de) * | 1999-07-14 | 2006-08-10 | Alza Corp., Mountain View | Neutrales lipopolymer und liposomale zusammensetzungen daraus |
EP1261361B1 (de) * | 2000-02-18 | 2006-06-14 | Yeda Research And Development Company, Ltd. | Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung |
WO2002086117A1 (en) * | 2001-04-20 | 2002-10-31 | The University Of Vermont | Compositions and methods to control bleeding |
CA2478066C (en) * | 2001-12-04 | 2009-09-08 | Ben-Gurion University Of The Negev Research And Development Authority | Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting |
-
2004
- 2004-04-15 PL PL04727664T patent/PL1633440T3/pl unknown
- 2004-04-15 DK DK04727664T patent/DK1633440T3/da active
- 2004-04-15 CA CA2522179A patent/CA2522179C/en not_active Expired - Fee Related
- 2004-04-15 PT PT04727664T patent/PT1633440E/pt unknown
- 2004-04-15 BR BRPI0409424A patent/BRPI0409424B8/pt active IP Right Grant
- 2004-04-15 JP JP2006507607A patent/JP2006523683A/ja active Pending
- 2004-04-15 DE DE602004013769T patent/DE602004013769D1/de not_active Expired - Lifetime
- 2004-04-15 AU AU2004229253A patent/AU2004229253B2/en not_active Expired
- 2004-04-15 EP EP04727664A patent/EP1633440B1/de not_active Expired - Lifetime
- 2004-04-15 MX MXPA05010926A patent/MXPA05010926A/es active IP Right Grant
- 2004-04-15 AT AT04727664T patent/ATE395101T1/de not_active IP Right Cessation
- 2004-04-15 CN CN2004800100998A patent/CN1774281B/zh not_active Expired - Lifetime
- 2004-04-15 ES ES04727664T patent/ES2307009T3/es not_active Expired - Lifetime
- 2004-04-15 WO PCT/IL2004/000327 patent/WO2004091723A1/en active IP Right Grant
- 2004-04-15 US US10/553,357 patent/US20070167359A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2006523683A (ja) | 2006-10-19 |
BRPI0409424B1 (pt) | 2018-05-02 |
BRPI0409424A (pt) | 2006-04-25 |
WO2004091723A1 (en) | 2004-10-28 |
EP1633440A1 (de) | 2006-03-15 |
AU2004229253B2 (en) | 2009-11-05 |
EP1633440B1 (de) | 2008-05-14 |
US20070167359A1 (en) | 2007-07-19 |
PT1633440E (pt) | 2008-08-25 |
CN1774281B (zh) | 2010-10-13 |
PL1633440T3 (pl) | 2008-12-31 |
CA2522179C (en) | 2012-02-14 |
CA2522179A1 (en) | 2004-10-28 |
ATE395101T1 (de) | 2008-05-15 |
BRPI0409424B8 (pt) | 2021-05-25 |
AU2004229253A1 (en) | 2004-10-28 |
DE602004013769D1 (de) | 2008-06-26 |
MXPA05010926A (es) | 2005-11-25 |
ES2307009T3 (es) | 2008-11-16 |
CN1774281A (zh) | 2006-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2476698A3 (de) | Peptidvakzinen für MPHOSPH1- oder DEPDC1-Polypeptide exprimierenden Krebs | |
ATE540973T1 (de) | Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung | |
DE602004014263D1 (de) | Rgd-angereicherte gelatine-ähnliche proteine mit verstärkter zellbindung | |
BR0007597A (pt) | Composição hipoalergênica contendo peptìdios tolerogênicos induzindo tolerância oral | |
ATE352559T1 (de) | Verfahren zur verminderung der immunogenität von proteinen | |
EP2711025A3 (de) | Selbstangeordnete Peptide mit Modifikationen und Verwendungsverfahren dafür | |
EP2039769A3 (de) | Antimikrobielle Peptide und Verwendungsverfahren | |
ATE368053T1 (de) | Antimikrobielle peptide | |
DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
ATE430161T1 (de) | Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung | |
DE60335726D1 (de) | Chromoprotein und fluoroproteine | |
DE69820449D1 (de) | T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen | |
JP2009542622A5 (de) | ||
DK1633440T3 (da) | Farmaceutisk sammensætning omfattende proteiner og/eller polypeptider og kolloidale partikler | |
WO2001005810A3 (de) | CYCLISCHE PEPTIDDERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿6? | |
ATE412745T1 (de) | Antiangiogene peptide vom n-terminus von endostatin | |
HK1046648A1 (en) | Vaccines containing hybrid polypeptides consistingof at least two different allergenic proteins | |
CA2071757A1 (en) | Implant compositions containing a biologically active protein, peptide or polypeptide | |
ATE474589T1 (de) | Angiogene peptide und ihre verwendungen | |
WO2007002233A3 (en) | Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau | |
EP1578772A4 (de) | Cytokine und cytokinrezeptoren mit reduzierter immunogenität | |
Stambuk et al. | Molecular recognition theory of the complementary (antisense) peptide interactions | |
ATE452903T1 (de) | Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten | |
ATE441713T1 (de) | Tumorantigenprotein und dessen verwendung | |
CA2163805A1 (en) | Novel activating factor of leukocytes |